TG THERAPEUTICS, INC. (TGTX) Spending and interest coverage
- R&D / revenue · 12 months: Value 28.24%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 10.15%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 28.24% | Research and development expense / revenue. Period ending 2026-06-30. $225.80M ÷ $799.54M × 100 ≈ 28.24% |
| Stock-based compensation / revenue · 12 months | 10.15% | Share-based compensation / revenue. Period ending 2026-06-30. $81.16M ÷ $799.54M × 100 ≈ 10.15% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 225.80M USD | Research and Development Expense |
| Revenue | 799.54M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 81.16M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 136.33M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $225.80M | $799.54M | $81.16M | $136.33M | (m) | 28.24% | 10.15% | (m) | (m) |
| 2026-03-31 | $162.25M | $700.35M | $69.65M | $149.50M | (m) | 23.17% | 9.94% | (m) | (m) |
| 2025-12-31 | $160.22M | $616.29M | $64.67M | $123.32M | (m) | 26.00% | 10.49% | (m) | (m) |
| 2025-09-30 | $142.90M | $531.90M | $60.97M | $102.78M | (m) | 26.87% | 11.46% | (m) | (m) |
| 2025-06-30 | $122.16M | $454.07M | $55.05M | $85.85M | (m) | 26.90% | 12.12% | (m) | (m) |
| 2025-03-31 | $107.93M | $386.39M | $48.17M | $59.82M | (m) | 27.93% | 12.47% | (m) | (m) |
| 2024-12-31 | $94.29M | $329.00M | $42.54M | $41.93M | (m) | 28.66% | 12.93% | (m) | (m) |
| 2024-09-30 | $87.87M | $264.79M | $39.98M | $-505.00K | (m) | 33.18% | 15.10% | (m) | (m) |
| 2024-06-30 | $82.48M | $346.72M | $37.39M | $101.84M | (m) | 23.79% | 10.78% | (m) | (m) |
| 2024-03-31 | $93.04M | $289.33M | $40.45M | $48.35M | $12.06M | 32.16% | 13.98% | 4.01× | Reported |
| 2023-12-31 | $76.19M | $233.66M | $37.93M | $20.63M | $12.62M | 32.61% | 16.23% | 1.64× | Reported |
| 2023-09-30 | $88.38M | $189.77M | $39.60M | $-18.94M | $13.05M | 46.57% | 20.87% | -1.45× | Reported |
| 2023-06-30 | $94.43M | $24.05M | $37.40M | $-168.69M | $10.98M | 392.60% | 155.51% | -15.36× | Reported |
| 2023-03-31 | $93.18M | $8.57M | $23.89M | $-162.96M | $10.37M | 1087.03% | 278.66% | -15.71× | Reported |
| 2022-12-31 | $125.35M | $2.79M | $19.18M | $-192.84M | $10.19M | 4500.97% | 688.87% | -18.92× | Reported |
| 2022-09-30 | $158.36M | $5.03M | $22.49M | $-233.72M | $8.41M | 3150.88% | 447.47% | -27.80× | Reported |
| 2022-06-30 | $189.53M | $6.96M | $29.50M | $-283.89M | $7.80M | 2722.74% | 423.76% | -36.41× | Reported |
| 2022-03-31 | $207.53M | $7.91M | $46.78M | $-322.44M | $6.40M | 2622.94% | 591.22% | -50.35× | Reported |
| 2021-12-31 | $222.58M | $6.69M | $61.27M | $-344.77M | $5.64M | 3327.54% | 916.04% | -61.15× | Reported |
| 2021-09-30 | $202.89M | $4.41M | $80.44M | $-338.61M | $5.85M | 4604.95% | 1825.67% | -57.88× | Reported |
| 2021-06-30 | $201.39M | $2.41M | $94.77M | $-339.20M | $6.42M | 8342.58% | 3925.97% | -52.83× | Reported |
| 2021-03-31 | $192.97M | $907.00K | $85.84M | $-312.55M | $7.03M | 21275.41% | 9464.06% | -44.48× | Reported |
| 2020-12-31 | $165.90M | $152.00K | $80.29M | $-273.59M | $6.33M | 109142.11% | 52821.71% | -43.23× | Reported |
| 2020-09-30 | $153.88M | $152.00K | $48.85M | $-224.77M | $6.94M | 101235.53% | 32140.79% | -32.40× | Reported |
| 2020-06-30 | $161.40M | $152.00K | $22.60M | $-199.91M | $6.87M | 106184.21% | 14867.76% | -29.12× | Reported |
| 2020-03-31 | $157.82M | $152.00K | $16.99M | $-184.61M | $5.71M | 103826.97% | 11175.00% | -32.31× | Reported |
| 2019-12-31 | $154.18M | $152.00K | $7.80M | $-169.06M | $5.29M | 101434.21% | 5131.58% | -31.98× | Reported |
| 2019-09-30 | $175.51M | $152.00K | $7.19M | $-185.24M | (m) | 115469.08% | 4727.63% | (m) | (m) |
| 2019-06-30 | $150.92M | $152.00K | $4.94M | $-190.09M | (m) | 99292.11% | 3248.68% | (m) | (m) |
| 2019-03-31 | $156.76M | $152.00K | $7.45M | $-167.51M | (m) | 103130.26% | 4898.03% | (m) | (m) |
| 2018-12-31 | $159.39M | $152.00K | $12.90M | $-174.40M | (m) | 104862.50% | 8486.84% | (m) | (m) |
| 2018-09-30 | $133.11M | (m) | $15.00M | $-151.28M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $126.86M | (m) | $20.06M | $-148.54M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $114.87M | (m) | $17.29M | $-132.62M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $102.53M | (m) | $15.95M | $-118.71M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $98.82M | (m) | $13.70M | $-111.71M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $93.47M | (m) | $11.65M | $-105.05M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $80.30M | (m) | $11.81M | $-92.64M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $69.23M | (m) | $7.51M | $-78.97M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $62.20M | (m) | $9.04M | $-72.58M | $916.73K | (m) | (m) | -79.17× | Reported |
| 2016-06-30 | $51.98M | (m) | $7.44M | $-61.48M | $951.71K | (m) | (m) | -64.60× | Reported |
| 2016-03-31 | $49.71M | (m) | $12.04M | $-62.57M | $977.48K | (m) | (m) | -64.01× | Reported |
| 2015-12-31 | $47.71M | (m) | $15.70M | $-63.18M | $972.74K | (m) | (m) | -64.95× | Reported |
| 2015-09-30 | $47.59M | (m) | $17.88M | $-64.26M | $965.50K | (m) | (m) | -66.56× | Reported |
| 2015-06-30 | $49.71M | (m) | $20.74M | $-67.87M | $953.76K | (m) | (m) | -71.17× | Reported |
| 2015-03-31 | $45.29M | (m) | $22.23M | $-62.72M | $942.02K | (m) | (m) | -66.58× | Reported |
| 2014-12-31 | $40.09M | (m) | $21.11M | $-55.72M | $930.70K | (m) | (m) | -59.87× | Reported |
| 2014-09-30 | $28.71M | (m) | $17.01M | $-44.98M | $936.79K | (m) | (m) | -48.01× | Reported |
| 2014-06-30 | $18.32M | (m) | $13.91M | $-32.18M | $942.53K | (m) | (m) | -34.15× | Reported |
| 2014-03-31 | $16.50M | (m) | $7.55M | $-26.86M | $947.76K | (m) | (m) | -28.34× | Reported |
| 2013-12-31 | $13.66M | (m) | $5.20M | $-22.97M | $952.89K | (m) | (m) | -24.10× | Reported |
| 2013-09-30 | $10.99M | (m) | $5.50M | $-18.68M | $940.92K | (m) | (m) | -19.85× | Reported |
| 2013-06-30 | $9.24M | (m) | $5.32M | $-16.75M | $928.97K | (m) | (m) | -18.03× | Reported |
| 2013-03-31 | $5.86M | (m) | $5.12M | $-13.22M | $917.07K | (m) | (m) | -14.42× | Reported |
| 2012-12-31 | $21.03M | (m) | $3.42M | $-26.90M | $905.74K | (m) | (m) | -29.69× | Reported |
| 2012-09-30 | $19.96M | (m) | $2.27M | $-23.76M | $683.94K | (m) | (m) | -34.74× | Reported |
| 2012-06-30 | $18.42M | (m) | $1.43M | $-21.08M | $455.36K | (m) | (m) | -46.28× | Reported |
| 2012-03-31 | $17.07M | (m) | $275.00K | $-18.27M | $-227.25K | (m) | (m) | (m) | Reported |
| 2011-12-31 | $327.28K | (m) | $86.49K | $-881.97K | $7.10K | (m) | (m) | -124.27× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |